Skip to main content

Advertisement

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

An Australian translational Study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (Avastin™) [ASCENT]

  • Stephen Clarke1Email author,
  • Matt Burge2,
  • Cassandra Cordwell3,
  • Peter Gibbs4,
  • William Reece5 and
  • Niall Tebbutt6
BMC Cancer201313:120

DOI: 10.1186/1471-2407-13-120

Received: 15 August 2012

Accepted: 8 March 2013

Published: 15 March 2013

Back to article

Open Peer Review reports

Pre-publication versions of this article and author comments to reviewers are available by contacting info@biomedcentral.com.

Original Submission
15 Aug 2012 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
2 Nov 2012 Reviewed Reviewer Report - Stephen Falk
13 Nov 2012 Reviewed Reviewer Report - Paul Ross
13 Nov 2012 Reviewed Reviewer Report - raffaele palmirotta
16 Dec 2012 Author responded Author comments - Cassandra Cordwell
Resubmission - Version 3
16 Dec 2012 Submitted Manuscript version 3
Publishing
8 Mar 2013 Editorially accepted
15 Mar 2013 Article published 10.1186/1471-2407-13-120

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article.. All previous versions of the manuscript and all author responses to the reviewers are also available.

You can find further information about the peer review system here.

Authors’ Affiliations

(1)
Royal North Shore Hospital
(2)
Royal Brisbane and Women Hospital
(3)
Roche Products, Pty. Limited (Australia)
(4)
Royal Melbourne Hospital
(5)
Covance Pty Ltd
(6)
Austin Health

Advertisement